Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Savara IncSVRA · Entity 4900 | Chief Fin. & Operating Officer | July 15, 2026 | July 24, 2026 |
| Strongbridge Biopharma plcSBBP · Entity 131608 | Chief Financial Officer | February 22, 2021 | February 23, 2021 |
| iBio, Inc.IBIO · Entity 6906 | See Remarks | November 11, 2022 | November 15, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Savara Inc
Report date July 15, 2026 · Filed July 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 328,977 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 35,000 · Balance 328,977 F1: Represents restricted stock units ("RSUs") that vest in full on July 15, 2028, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.81 · Expires 2036-07-15 | Direct | 70,000 |
Reported balance
After 2026-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-15 · Grant · Acquired 70,000 · Balance 70,000 F2: The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of July 15, 2026, subject to the reporting person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that vest in full on July 15, 2028, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F2: The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of July 15, 2026, subject to the reporting person's continued service with the Issuer.
Strongbridge Biopharma plc
Report date February 22, 2021 · Filed February 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 181,333 |
Reported balance
After 2021-02-22 transaction · row 1
1 source rowRow 1 · 2021-02-22 · Tax withholding · Disposed 6,978 · Balance 181,333 F1: Shares withheld by Strongbridge Biopharma plc to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by Strongbridge Biopharma plc to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units.
iBio, Inc.
Report date November 11, 2022 · Filed November 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,165 |
Reported balance
After 2022-11-11 transaction · row 1
1 source rowRow 1 · 2022-11-11 · Grant · Acquired 100,057 · Balance 102,165 F1: Consists of 100,057 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 100,057 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan, (the "2020 Plan"). Each RSU represents a contingent right to receive one share of Common Stock. The 100,057 RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Corporation's 2023 objectives, as defined by the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of 100,057 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 100,057 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan, (the "2020 Plan"). Each RSU represents a contingent right to receive one share of Common Stock. The 100,057 RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Corporation's 2023 objectives, as defined by the Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 24, 2026 22:24 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $5.81 | $0.00 |
DisclosureSEC source: 0001193125-26-316442 · ownership.xml · derivative · entry 2 Lutz Robert Matthew · CIK 0001786203 · Chief Fin. & Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-07-15 F2 · derivative.exercise_date: The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of July 15, 2026, subject to the reporting person's continued service with the Issuer. Read SEC document |
| July 15, 2026 Filed Jul 24, 2026 22:24 UTC | Savara Inc SVRA · Entity 4900 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-316442 · ownership.xml · nonDerivative · entry 1 Lutz Robert Matthew · CIK 0001786203 · Chief Fin. & Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 328,977 F1 · shares: Represents restricted stock units ("RSUs") that vest in full on July 15, 2028, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 14, 2025 Filed Dec 16, 2025 22:26 UTC | Savara Inc SVRA · Entity 4900 | Tax withholdingCommon Stock | 67,760 | $6.92 | $468,899.20 |
DisclosureSEC source: 0001193125-25-321182 · ownership.xml · nonDerivative · entry 1 Lutz Robert Matthew · CIK 0001786203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,977 F1 · shares: Represents shares withheld by the Issuer in connection with the reporting person's net share settlement to satisfy tax liability based upon the vesting of previously awarded restricted stock units. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 21:35 UTC | Savara Inc SVRA · Entity 4900 | Tax withholdingCommon Stock | 38,263 | $2.83 | $108,284.29 |
DisclosureSEC source: 0000950170-25-021312 · ownership.xml · nonDerivative · entry 1 Lutz Robert Matthew · CIK 0001786203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 361,737 F1 · shares: Represents shares withheld by the Issuer in connection with the reporting person's net share settlement to satisfy tax liability based upon the vesting of previously awarded restricted stock units. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 23:05 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0000950170-24-136790 · ownership.xml · derivative · entry 2 Lutz Robert Matthew · CIK 0001786203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-12-12 F2 · derivative.exercise_date: The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 12, 2024, subject to the reporting person's continued service with the Issuer. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 23:05 UTC | Savara Inc SVRA · Entity 4900 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-136790 · ownership.xml · nonDerivative · entry 1 Lutz Robert Matthew · CIK 0001786203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 F1 · shares: Represents restricted stock units ("RSUs") that vest in full on December 12, 2026, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 22:51 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0001209191-23-058854 · doc4.xml · derivative · entry 2 Lutz Robert Matthew · CIK 0001786203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-12-14 F2 · derivative.exercise_date: The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 14, 2023, subject to the reporting person's continued service with the Issuer. Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 22:51 UTC | Savara Inc SVRA · Entity 4900 | GrantCommon Stock | 160,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-058854 · doc4.xml · nonDerivative · entry 1 Lutz Robert Matthew · CIK 0001786203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 F1 · shares: Represents restricted stock units ("RSUs") that vest in full on December 14, 2025, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 21:31 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $2.53 | $0.00 |
DisclosureSEC source: 0001209191-23-013677 · doc4.xml · derivative · entry 2 Lutz Robert Matthew · CIK 0001786203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2033-02-24 F2 · derivative.exercise_date: The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of February 13, 2023, subject to the reporting person's continued service with the Issuer. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 21:31 UTC | Savara Inc SVRA · Entity 4900 | GrantCommon Stock | 140,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-013677 · doc4.xml · nonDerivative · entry 1 Lutz Robert Matthew · CIK 0001786203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 F1 · shares: Represents restricted stock units ("RSUs") that vest in full on February 13, 2025, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 13:33 UTC | iBio, Inc. IBIO · Entity 6906 | GrantCommon Stock | 100,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-118975 · tm2230588-2_4seq1.xml · nonDerivative · entry 1 Lutz Robert Matthew · CIK 0001786203 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,165 F1 · shares: Consists of 100,057 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 100,057 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan, (the "2020 Plan"). Each RSU represents a contingent right to receive one share of Common Stock. The 100,057 RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Corporation's 2023 objectives, as defined by the Board of Directors. Read SEC document |
| August 29, 2022 Filed Aug 31, 2022 20:01 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001104659-22-096529 · tm2224840-2_4seq1.xml · derivative · entry 1 Lutz Robert Matthew · CIK 0001786203 · See Remark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2032-08-28 F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc. F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:12 UTC | iBio, Inc. IBIO · Entity 6906 | SaleCommon Stock | 24,625 | $0.35 | $8,510.40 |
DisclosureSEC source: 0001104659-22-033320 · tm229111-2_4seq1.xml · nonDerivative · entry 1 Lutz Robert Matthew · CIK 0001786203 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,375 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer"). F1 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3410 to $0.3481 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2021 Filed Aug 26, 2021 00:32 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001104659-21-109470 · tm2125787-4_4seq1.xml · derivative · entry 1 Lutz Robert Matthew · CIK 0001786203 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-08-22 F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc. F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 02:30 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001104659-21-032333 · tm218800d2_4seq1.xml · derivative · entry 2 Lutz Robert Matthew · CIK 0001786203 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2031-03-04 F2 · derivative.exercise_date: The stock option vests as follows: (1) 25% of the options granted will vest after one year of employment with the Company; and (2) after one year of employment with the Company, 6.25% of the options granted will vest for each additional three (3) months of employment, subject to the conditions of the 2020 Plan and the stock option grant agreement. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 02:30 UTC | iBio, Inc. IBIO · Entity 6906 | GrantCommon Stock | 232,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-032333 · tm218800d2_4seq1.xml · nonDerivative · entry 1 Lutz Robert Matthew · CIK 0001786203 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,000 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of common stock of iBio, Inc. (the "Company"). The restricted stock units vest in three equal annual installments beginning March 4, 2022, subject to the conditions of the iBio, Inc. 2020 Omnibus Equity Incentive Plan (the "2020 Plan") and the restricted stock unit grant agreement. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 17:16 UTC | Strongbridge Biopharma plc SBBP · Entity 131608 | Tax withholdingOrdinary Shares | 6,978 | $3.62 | $25,260.36 |
DisclosureSEC source: 0001179110-21-002120 · edgar.xml · nonDerivative · entry 1 Lutz Robert Matthew · CIK 0001786203 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,333 F1 · shares: Shares withheld by Strongbridge Biopharma plc to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 08:35 UTC | Strongbridge Biopharma plc SBBP · Entity 131608 | GrantOrdinary Shares | 147,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-000428 · edgar.xml · nonDerivative · entry 1 Lutz Robert Matthew · CIK 0001786203 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,311 F1 · shares: Represents a grant of restricted stock units, which vest in full on January 7, 2023, provided the Reporting Person is employed by the Issuer on such date. Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 18:25 UTC | Strongbridge Biopharma plc SBBP · Entity 131608 | GrantEmployee Stock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001179110-20-000875 · edgar.xml · derivative · entry 1 Lutz Robert Matthew · CIK 0001786203 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2030-01-27 F1 · derivative.exercise_date: This option vests in sixteen equal quarterly installments beginning April 27, 2020, provided the Reporting Person is employed by the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.